Norton Neuroscience Institute is one of six sites nationwide chosen to pilot a new Brain Health Navigator program aimed at creating a worldwide model to prevent, diagnose and treat Alzheimer’s disease. The program — funded and pioneered by the Davos Alzheimer’s Collaborative — provides resources for patients and providers at these six sites. “This collaborative effort continues…
A recent study published in the The Journal of Prevention of Alzheimer’s Disease provides detailed insight into clinicians’ and patients’ initial experience with lecanemab, the first Food and Drug Administration-approved antiamyloid monoclonal antibody infusion proven to slow cognitive and functional decline due to Alzheimer’s disease. Conducted at the Norton Neuroscience Institute Memory Center, the study…
David A. Robertson, M.D., neurologist and neuroimmunologist, has joined Norton Neuroscience Institute Hussung Family Multiple Sclerosis Center. Dr. Robertson is originally from McPherson, Kansas. He graduated from the University of Kansas School of Medicine in 2004 and completed an internship in internal medicine and a residency in neurology, both at Vanderbilt University in Nashville, Tennessee. As a…
Norton Neuroscience Institute will be the first and only facility in Kentucky to offer MRI-guided high-frequency focused ultrasound for essential tremor and tremor-dominant Parkinson’s disease. This life-changing treatment has been shown to dramatically improve tremor symptoms for patients starting on the day of treatment. The technology will be purchased with $2.8 million in funding through the Norton Healthcare Foundation. High-frequency…
A study showed that about 45% of dementias are preventable through lifestyle modifications. The societal impacts of this research include reducing financial burdens on the health care system, improving social participation and population health, and improving quality of life for millions of Americans. “Primary care clinicians can now start the conversation about cognitive health with…
New monoclonal antibody therapies targeting beta-amyloid deposition in the brain have shown success in slowing the progression of Alzheimer’s disease, though the risk of serious side effects necessitates careful evaluation and discussion before initiating treatment.. In January 2023, the Food and Drug Administration (FDA) gave accelerated approval to lecanemab, which goes by the brand name…
Neuromuscular disorders are conditions that affect the structure and function of the peripheral nervous system, as well as all motor and sensory nerves. The predominant symptom of this group of disorders is progressive muscle weakness. Secondary symptoms may include muscular atrophy and disturbances in sensation, which may present as tingling or numbness. The developments in…
Physician assistant Kendall M. Wasz, PA-C, has joined the memory care team at Norton Neuroscience Institute. Kendall holds Master of Science degree in physician assistant studies from the University of Kentucky, Lexington, and earned her bachelor’s degree at Miami University, Oxford, Ohio. Kendall brings a deeply personal and compassionate approach to the field of dementia…
Norton Research Institute will expand research efforts with the unveiling of the new Norton Research Institute Clinical & Translational Research Laboratory. The 7,200-square-foot facility, located inside Norton Healthcare Pavilion in downtown Louisville, will afford ample space and resources for scientists to conduct cutting-edge research, with the goal of producing more meaningful, applicable results directly benefiting patient…
Safer controlled substance prescribing begins with a thorough patient workup, an appropriate diagnosis and a comprehensive treatment plan, according to Kelly C. Cooper, M.D., an addiction medicine specialist with Norton Behavioral Medicine. “We just tend to go for the pills first. And it’s not just as providers, it’s patients as well,” Dr. Cooper said during…
The patient A 64-year-old woman tripped after “missing a step,” fracturing her left tibial plateau and resulting in deformity of the joint. This was managed conservatively, with a leg brace removing weight from the extremity. She developed persistent numbness and tingling in her left leg, as well as weakness. She was evaluated in the Norton…
In 2023, the Food and Drug Administration (FDA) approved lecanemab (brand name Leqembi) for the treatment of Alzheimer’s disease. Lecanemab is the first widely used medication in a new class of anti-amyloid agents for the treatment of patients with mild cognitive impairment (MCI) or early stages of Alzheimer’s disease. This is the first new Alzheimer’s…